ClinicalTrials.gg
RecruitingNCT05858606PAG PETIUpdated Nov 9, 2026

Multidisciplinary Evaluation and a Genome-wide Analysis in a Cohort of Idiopathic Short Stature Patients

An interventional study of Evaluation of the prevalence of truly (authentified) idiopathic short stature after multidisciplinary clinico-radiological evaluation and analysis in a multidisciplinary consultation meeting via a secure platform (ShareConfrère) for evaluation by multidisciplinary team in Idiopathic Short Stature, sponsored by University Hospital, Montpellier. Recruiting at 4 sites in France. Open to participants aged 4 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by University Hospital, Montpellier · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.
Updated Nov 9, 20263 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Not applicable
Ages
4 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies in Mucopolysaccharidosis IV with a site in France — 8 open to participants now, 8 under way, 1 of them phase 3. Mucopolysaccharidosis IV · France.

Planned enrollment
3rd of 11
200 · median 135
Started
2026
with 1 other
No phase
2 of 19
1 open now
Registered
13th of 19
by date
Lead sponsor
1 of 19
University Hospital, Montpellier

Among the 19 studies in Mucopolysaccharidosis IV with a site in France, this one is the 3rd largest by planned enrollment of the 11 interventional ones that give a count, is one of 2 that started in 2026, is one of 2 with no phase, and was the 13th registered.

Mucopolysaccharidosis IV

101 studies on the registry are indexed under Mucopolysaccharidosis IV; 27 are open to participants now.

Browse Mucopolysaccharidosis IV studies →

Open to participants now

8 of the 19 studies in Mucopolysaccharidosis IV with a site in France are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 20 Mucopolysaccharidosis IV studies recruiting now, 9 (45%) set no upper age limit and 7 (35%) stop at 75 or younger; 15 take children under 18; 7 take healthy volunteers.

This study: 4 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Mucopolysaccharidosis IV with a site in France, or all of them as a file.
02

Study summary

This trial aims to evaluate the prevalence of idiopathic short stature among children whose growth is above -2,5SD (AFPA- CRESS/Inserm -CompuGroup Medical 2018 curve) or above -2SD of the parental target size (taking child gender into account), after exclusion of classical pediatric and endocrinologic pathologies, and to evaluate the prevalence of monogenic causes of idiopathic short stature. A two-step study will be performed. The first one consists in a standardized multidisciplinary clinico-radiological evaluation of those children to evaluate the real prevalence of idiopathic short stature (ISS) among these patients. The second step consists in performing a whole genome sequencing analysis in the 30 first patients for whom the diagnosis of ISS is confirmed.

Read the detailed description

Detailed description: Establishing the etiological diagnosis of short stature is an important step to guide the therapeutic management of patients and to propose appropriate genetic counseling. Short stature can be a symptom of many pathologies. However, in the majority of cases (80%), no specific etiology is found during a pediatric clinical investigation. In this case, the diagnosis of "idiopathic" short stature is performed. However, the diagnostic and therapeutic management of short stature after exclusion of classical pediatric causes is extremely heterogeneous and there are currently no consensual recommendations. A substantially higher proportion of diagnosed patients is therefore expected, along with more standardized clinical and genetic procedures. Additionally, in recent years, new methods of genetic investigation (gene panel, whole exome or whole genome sequencing analysis) have made it possible to identify many genetic variants associated with apparently isolated short stature. So far, none of the publications reporting next-generation sequencing analysis have focused on patients with authentic idiopathic short stature, i.e. without associated bone anomalies or syndromic features, and are often focused on only a subset of target genes.

This trial aims at estimating the prevalence of idiopathic short stature among children whose growth is above -2,5SD (AFPA- CRESS/Inserm -CompuGroup Medical 2018 curve) or above -2SD of the parental target size, after exclusion of classical pediatric and endocrinologic pathologies, and to evaluate the prevalence of monogenic causes of idiopathic short stature. A two-step study will be performed. The first one consists in a multidisciplinary clinico-radiological evaluation of those children to evaluate the real prevalence of idiopathic short stature (ISS) among these patients. The second step consists in performing a whole genome sequencing analysis in the 30 first patients for whom the diagnosis of authentic ISS is confirmed.

All patients will have:

  • a pre-inclusion visit
  • an inclusion visit after which the multidisciplinary clinico-radiological evaluation will be held

This analysis will assign patients to the diagnosis of either:

  1. non-idiopathic short stature (diagnosis of constitutional bone disease or syndromic disorder)
  2. authentic idiopathic short stature

A teleconsultation (1) to explain to the parents the conclusions of the multidisciplinary clinico-radiological evaluation.

This teleconsultation will be followed for all patients in the "non-idiopathic short stature" group, by a visit to take samples for genetic analysis in the context of clinical care, followed by a teleconsultation (2) to give them and explain the results

This teleconsultation will be followed for the first 30 patients in the "authentified idiopathic short stature" group, by a visit to take samples for whole genome analysis in the context of research, followed by a teleconsultation (2) to return the results.

03

Conditions studied

  • Idiopathic Short Stature

Keywords

  • idiopathic short stature
  • whole genome analysis
  • monogenic conditions
  • syndromic disorders
  • skeletal dysplasia
04

Who can participate

Ages eligible
4 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Children aged 4 to 18 years
  • 2 sexes
  • Height less than -2.5DS (standard deviations of the AFPA- CRESS/Inserm -CompuGroup Medical 2018 curve) or less than -2DS of the TCP (parental target height, corresponding to the average of parental heights +6.5 cm in boys, -6.5 cm in girls)
  • Normal karyotype + FISH SHOX for girls
  • Previously performed:celiac disease antibodies, WBC-, CRP, blood ionogram, creatinine, blood calcium, blood phosphorus, ASAT, ALAT, PAL, PTH, TSH, T4L, growth hormone test normal according to the standards of the laboratory of the CHU of Montpellier
  • Acceptance of X-rays, in addition to those already performed as part of the care, which will not be repeated if necessary: spine front and profile, pelvis front, 1 upper limb front, 1 lower limb front F, hands and feet front
  • Acceptance of photographs: whole body with underwear, face face and profile, 2 faces of hands; feet, face
  • Acceptance of blood samples for the child and the 2 parents (trio)
  • Consent signed by both parents

Exclusion criteria

Exclusion Criteria:

  • Intellectual disability (IQ below 70)
  • Cardiac, renal, digestive or cerebral malformation, cleft lip or palate, hearing or visual impairment, epilepsy
  • Renal or cardiac insufficiency, digestive or chronic inflammatory pathology
  • Previously established genetic diagnosis
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    200 patients with idiopathic short stature,

    200 patients with apparently idiopathic short stature,

    Diagnostic Test: Evaluation of the prevalence of truly (authentified) idiopathic short stature after multidisciplinary clinico-radiological evaluation · Procedure: analysis in a multidisciplinary consultation meeting via a secure platform (ShareConfrère) for evaluation by multidisciplinary team · Genetic: Whole genome analysis for authentified idiopathic short stature

Interventions

  • Diagnostic testEvaluation of the prevalence of truly (authentified) idiopathic short stature after multidisciplinary clinico-radiological evaluation

    1. pre-inclusion consultation 2. inclusion consultation * personal history * height, weight, cranial perimeters, and spans of both parents * clinical examination of the child * photographs of the child * additional X-rays

  • Procedureanalysis in a multidisciplinary consultation meeting via a secure platform (ShareConfrère) for evaluation by multidisciplinary team

    multidisciplinary team (geneticist, orthopedist, radiologist, pediatric endocrinologist) which will assign each patient an orientation: * either to the non idiopathic short stature group (syndromic diagnostic orientation or to a constitutional bone pathology) * or to the authentified idiopathic short stature group

  • GeneticWhole genome analysis for authentified idiopathic short stature

    For the first 30 patients included in the authentified idiopathic short stature group, a whole genome analysis in trio (child + parents) will be performed as part of the research. For these 30 patients in the authentified idiopathic short stature group, the teleconsultation carried out for the submission of the multidisciplinary consultation meeting conclusions will make it possible to establish the family tree, to explain the interest and limits of the analysis, and to submit the consents dedicated to the genetic analysis.

06

What researchers measure

Primary outcomes

  1. proportion of patients with authentified idiopathic short stature after multidisciplinary clinical-radiological analysis

    Primary endpoint: The primary outcome is the proportion of patients with authentified idiopathic short stature after multidisciplinary clinical-radiological analysis (including geneticist, orthopedist, pediatric endocrinologist, radiologist) performed during a dedicated Multidisciplinary Consultation Meeting (MCM)

    Time frame: 3 years

Secondary outcomes

  1. Genome positivity rate

    Genome positivity rate (positive diagnosis of pathogenic variation or probably pathogenic variation variants involved in the phenotype) in the group of 30 patients with authentified idiopathic short stature patients in whom the genome analysis was performed

    Time frame: 3 years

  2. Rate of positivity of molecular analyses prescribed as part of the care following the PCR

    Rate of positivity of molecular analyses prescribed as part of the care following the PCR (positive diagnosis of pathogenic or probably pathogenic variants involved in the phenotype) for patients with non-idiopathic short stature

    Time frame: 3 years

  3. Rate of modification of management by the results of genome analysis

    Rate of modification of management by the results of genome analysis in the group of 30 patients with authentified idiopathic short stature in whom genome analysis has been performed

    Time frame: 3 years

  4. Type of change in management due to genome analysis results

    Type of change in management due to genome analysis results: initiation/withdrawal of treatment, referral to organ specialist for specific multidisciplinary management (patients with authentified idiopathic short stature/ Genome+)

    Time frame: 3 years

  5. Rate of change in management by results of molecular analysis

    Rate of change in management by results of molecular analysis performed in a patient-care context for those with non-idiopathic short stature

    Time frame: 3 years

  6. Type of management modification by molecular analysis resultscare context for those with non-idiopathic short stature

    Type of management modification by molecular analysis results: initiation/withdrawal of treatment, referral to organ specialist for specific multidisciplinary management (patients with non-idiopathic short stature).

    Time frame: 3 years

  7. Parental satisfaction

    Parental satisfaction will be assessed using a Visual Analog Scale (VAS) ranging from 0 to 10, where 0 indicates "not satisfied at all" and 10 indicates "completely satisfied." Higher scores indicate greater parental satisfaction. Assessments will be conducted following teleconsultations (Teleconsultation 1 and Teleconsultation 2).

    Time frame: 3 years

  8. Variants within the same gene identified in at least 2 patients by whole genome analysis

    Variants within the same gene identified in at least 2 patients by whole genome analysis in the group of 30 patients with authentified idiopathic short stature in whom genome analysis has been performed

    Time frame: 3 years

07

Study locations

4 of 4 sites recruiting
  • Endocrinologie et Diabétologie pédiatrique - Hôpital Kremlin Bicêtre - APHP
    Le Kremlin-Bicêtre, 94270, France
    Recruiting
  • HCL
    Lyon, France
    Recruiting
  • Service de Génétique Médicale - Arnaud de Villeneuve
    Montpellier, 34295, France
    Recruiting
  • Unité d'Endocrinologie, Maladies Osseuses et Génétique - Hôpital des Enfants, CHU de Toulouse
    Toulouse, 31059, France
    Recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Mar 2029, 36 months after the start.

Of 19 interventional studies with no phase under Mucopolysaccharidosis IV, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 13. This study's planned 36 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 7, 2023
First posted
May 15, 2023
StartActual
Mar 16, 2026
Primary completionEst.
Mar 2029
CompletionEst.
Mar 2029
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
3 sites added
Show 3 added (3 France)
  • Endocrinologie et Diabétologie pédiatrique - Hôpital Kremlin Bicêtre - APHP · Le Kremlin-Bicêtre, France
  • HCL · Lyon, France
  • Unité d'Endocrinologie, Maladies Osseuses et Génétique - Hôpital des Enfants, CHU de Toulouse · Toulouse, France
Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    3 sites added
    Show 3 added (3 France)
    • Endocrinologie et Diabétologie pédiatrique - Hôpital Kremlin Bicêtre - APHP · Le Kremlin-Bicêtre, France
    • HCL · Lyon, France
    • Unité d'Endocrinologie, Maladies Osseuses et Génétique - Hôpital des Enfants, CHU de Toulouse · Toulouse, France
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05858606
Responsible party
Sponsor
First posted
May 15, 2023
Start date
Mar 16, 2026
Primary completion
Mar 2029 (estimated)
Completion
Mar 2029 (estimated)
Last update
Nov 9, 2026

Study contacts

Marjorlaine WILLEMS, MD
Contact
m-willems@chu-montpellier.fr
+33467336367

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion